New drug combo trial offers hope for Tough-to-Treat cancers

NCT ID NCT06535607

Recruiting now Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

Summary

This study is testing a new drug called volrustomig, both by itself and combined with chemotherapy, for people with advanced solid tumors that have spread. It is enrolling about 257 adults with specific advanced cancers, including cervical, head and neck, esophageal, and a type of lung lining cancer called mesothelioma. The main goals are to see if the treatment shrinks tumors and is safe for patients.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Research Site
WITHDRAWN

Los Angeles, California, 90025, United States
Research Site
NOT_YET_RECRUITING

Baltimore, Maryland, 21201, United States
Research Site
NOT_YET_RECRUITING

Stony Brook, New York, 11794, United States
Research Site
NOT_YET_RECRUITING

Columbus, Ohio, 43210, United States
Research Site
RECRUITING

Ijuí, 98700-000, Brazil
Research Site
RECRUITING

Londrina, 86015-520, Brazil
Research Site
RECRUITING

São Caetano do Sul, 09541-270, Brazil
Research Site
RECRUITING

Vitória, 29043-260, Brazil
Research Site
NOT_YET_RECRUITING

Anyang, 455000, China
Research Site
NOT_YET_RECRUITING

Beijing, 100142, China
Research Site
ACTIVE_NOT_RECRUITING

Beijing, 100730, China
Research Site
RECRUITING

Beijing, 100730, China
Research Site
RECRUITING

Beijing, CN-100730, China
Research Site
WITHDRAWN

Bengbu, 233004, China
Research Site
WITHDRAWN

Changchun, 130021, China
Research Site
NOT_YET_RECRUITING

Changchun, 130021, China
Research Site
RECRUITING

Changsha, 410003, China
Research Site
ACTIVE_NOT_RECRUITING

Changsha, 410008, China
Research Site
RECRUITING

Changsha, 410008, China
Research Site
COMPLETED

Changsha, 410013, China
Research Site
ACTIVE_NOT_RECRUITING

Chengdu, 610041, China
Research Site
RECRUITING

Chengdu, 610072, China
Research Site
RECRUITING

Chongqing, 400030, China
Research Site
WITHDRAWN

Chongqing, 400030, China
Research Site
ACTIVE_NOT_RECRUITING

Dongguan, 523009, China
Research Site
RECRUITING

Dongguan, 523009, China
Research Site
COMPLETED

Fuzhou, 350011, China
Research Site
NOT_YET_RECRUITING

Fuzhou, 350014, China
Research Site
ACTIVE_NOT_RECRUITING

Hangzhou, 310022, China
Research Site
RECRUITING

Hangzhou, 310022, China
Research Site
WITHDRAWN

Hefei, 230031, China
Research Site
RECRUITING

Jining, 272029, China
Research Site
RECRUITING

Kunming, 650118, China
Research Site
RECRUITING

Nanchang, 330006, China
Research Site
NOT_YET_RECRUITING

Nanjing, 210009, China
Research Site
ACTIVE_NOT_RECRUITING

Nanning, 530021, China
Research Site
RECRUITING

Nanning, 530021, China
Research Site
RECRUITING

Shandong, 250117, China
Research Site
RECRUITING

Shandong, China
Research Site
ACTIVE_NOT_RECRUITING

Shandong, China
Research Site
NOT_YET_RECRUITING

Shandong, China
Research Site
ACTIVE_NOT_RECRUITING

Shanghai, 200120, China
Research Site
RECRUITING

Shanghai, 200120, China
Research Site
RECRUITING

Shenyang, 110004, China
Research Site
ACTIVE_NOT_RECRUITING

Tianjin, 300060, China
Research Site
RECRUITING

Tianjin, 300060, China
Research Site
RECRUITING

Wuhan, 430022, China
Research Site
ACTIVE_NOT_RECRUITING

Wuhan, 430022, China
Research Site
RECRUITING

Wuhan, 430030, China
Research Site
RECRUITING

Wuhan, 430040, China
Research Site
RECRUITING

Wuhan, 430079, China
Research Site
RECRUITING

Wuhou District, 610041, China
Research Site
NOT_YET_RECRUITING

Zhengzhou, 450008, China
Research Site
RECRUITING

Namdong-gu, 21565, South Korea
Research Site
RECRUITING

Seoul, 03722, South Korea
Research Site
NOT_YET_RECRUITING

Taichung, Taiwan
Research Site
RECRUITING

Taipei, 112, Taiwan
Research Site
RECRUITING

Hanoi, 100000, Vietnam
Research Site
RECRUITING

Ho Chi Minh City, 700000, Vietnam

Conditions

Explore the condition pages connected to this study.

CERVICAL CANCER HEAD AND NECK SQUAMOUS CELL CARCINOMA SUB-STUDY 1 CERVICAL CANCER (VOLRUSTOMIG MONOTHERAPY) SUB-STUDY 2 HEAD AND NECK SQUAMOUS CELL CARCINOMA (VOLRUSTOMIG MONOTHERAPY) SUB-STUDY 3 HEAD AND NECK SQUAMOUS CELL CARCINOMA (VOLRUSTOMIG IN COMBINATION WITH CHEMOTHERAPY) SUB-STUDY 4 ESOPHAGEAL SQUAMOUS CELL CARCINOMA (VOLRUSTOMIG IN COMBINATION WITH CHEMOTHERAPY) SUB-STUDY 5 UNRESECTABLE PLEURAL MESOTHELIOMA (VOLRUSTOMIG MONOTHERAPY)